Access to Medicines responds to IPHA’s concerns that Irish patients aren’t getting access to medicines quickly enough. We agree!

The Irish Pharmaceutical Healthcare Association (IPHA) wrote an article about how “Irish patients are not getting access to medicines quickly enough”.

We agree, they aren’t. But this is due to monopolies, high drug prices and failing to meet cost effectiveness criteria. Read our response here: …

IPHA original article:

The Irish Times view on drug prices: Big Pharma’s hostages

An editorial from The Irish Times on high drug prices. An important step in recognising the issues we face due to the current intellectual property incentivisation model. 

"Rising prices of new medicines are having a profound impact globally and are now exceeding the capacity of even the wealthiest of countries to pay, a recent Dublin conference on drug prices heard."

Ellen t' Hoen, a leading IP expert at our Access to Medicines Conference told the Irish Times that Pharma frequently holds governments in a "hostage situation" by using fear tactics to discourage opposition to high drug prices. 

We welcome the Editor's position on opening dialogue for the exploration of alternative drug pricing models.

"Yet the presence of so many drug manufacturers in Ireland means we are in a unique position to open a dialogue with industry to explore alternative models for the pricing of medicines."

Full article here:

Fear and secrecy used to drive medicine costs – conference told

The Irish Times came to our Access to Medicines Conference to ask our expert panelists about high drug prices. Ellen t' Hoen, a Dutch expert in intellectual property law and Yannis Natsis, policy manager of the European Health Alliance both call for greater "transparency across the sector" and a "need to change the way we incentivise medical R&D.”

Find the full link here:

Price pressure and new medicines

Access to Medicines Ireland has written a Letter to the Editor about their previous article entitled, 'Price pressure keeps nine new drugs from Irish patients'. Dr. Kieran Harkin lays out what the Irish government can do to greatly reduce the cost of these drugs and make them available to the patients who need them. 

Read our Letter to the Editor (30/04/2018) here:

Read the original article in the Irish Times, written by Dominic Coyle (23/04/2018) here:

Join us at our second annual Access to Medicines Ireland conference

Rising prices of new medicines are having a profound impact globally and are now exceeding the capacity of even the wealthiest of countries to pay. A panel of leading international experts, patient advocates and industry will come together in Dublin on the 2nd of May to discuss the current model of drugs development and propose interventions and alternative models with the potential to dramatically lower the prices of new medicines.

There will be 2 panels followed by Q&A and refreshments. This conference hopes to engage and inform all stakeholders - government, policy-makers, health care professionals, industry, NGOs, civil society groups and members of the public alike.

Please register on our Eventbrite page. Few places left!

Find photos of our event here:

Making Medicines Work

Dr. Ciara Conlon, Co-Founder of Access to Medicines Ireland wrote a forum article for Comhlamh highlighting that high drug prices aren't a result of manufacturing costs but what the market can bear.

"The hepatitis C drug Sofosbuvir, which is sold in the US for $1,000 (€930) a pill, is being made and sold at a profit in India for less than $5 a pill."

The article also proposes alternative models for incentivising R&D and making drug prices more affordable.

"New incentives for R&D such as grants, prizes and intellectual property pools aim to de-link the cost of R&D from the price of the medicine at the end."

For the full article: